期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

抗2型糖尿病新药利拉利汀 被引量：8

Linagliptin:a new agent for type 2 diabetic treatment
下载PDF
导出
摘要 利拉利汀是继西他列汀、沙格列汀后的二肽基肽酶-4抑制剂,与饮食和运动结合用于改善2型糖尿病患者的血糖控制能力。现有临床研究表明,利拉利汀是一个口服有效、可能有市场前景的药物。文中对利拉利汀的作用机制、药效学、药代动力学、药物相互作用、临床评价和安全性等进行综述。 Linagliptin,another dipeptidyl peptidase-4 inhibitor after sitagliptin and saxagliptin,has been marketed.It is indicated as an adjunct to diet and exercises to improve glycemic control in patients with type 2 diabetes mellitus.Clinical studies show that it is proved as an orally active and safe agent.The mechanism,pharmacodynamics,pharmacokinetics,drug interaction,clinical evaluation and safety of linagliptin are reviewed.
作者 黄占波 王丹 刘婷立 宋冬梅
机构地区 辽宁科技学院 沈阳亿灵医药科技有限公司
出处 《实用药物与临床》 CAS 2012年第8期513-515,共3页 Practical Pharmacy and Clinical Remedies
关键词 利拉利汀 二肽基肽酶-4抑制剂 2型糖尿病 Linagliptin Dipeptidyl peptidase-4 inhibitor Type 2 diabetes
分类号 R977.15 [医药卫生—药品]
  • 相关文献

参考文献12

  • 1Internation Diabetes Federation. Foreword of the diabetes atlas ( 5th edition) [ EB/OL ]. [ 2011-11-14 ]. http ://www. idf. org/diabetesatlas/content/foreword-0.
  • 2FDA. Linagliptin [ EB/OL ]. [ 2011-05-02 ]. http ://www. ac- cessdata, fda. gov/drugsatfda_ docs/label/2011/2012801bl. pdf.
  • 3Idris I, Donnelly R. Dipeptidyl peptidase-lV inhibitors:a major new class of oral antidiabetic drug [ J ]. Diabetes Obes Metab, 2007,9(2) :153-165.
  • 4Drucker DJ, Nauck MA. The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibi- tors in type 2 diabetes [ J]. Lancet, 2006,368 ( 9548 )-: 1696- 1705.
  • 5Lambeir AM, Durinx C, Scharpe S, et al. Dipeptidyl-peptidase Ⅳ from bench to bedside:an update on structural properties, functions, and clinical aspects of the enzyme DPP Ⅳ [ J ]. Crit Rev Clin Lab Sci, 2003,40 ( 3 ) :209 -294.
  • 6Gorrell MD, Gysbers V, Mccaughan GW. CD26 : a multifunc- tional integral membrane and secreted protein of activated lym- phocytes[J]. Scand J Immuno1,2001,54 (3) :249-264.
  • 7Thomas L, Eckhardt M, Langkopf R, et al. ( R ) -8 - ( 3-amino- piperidin-l-yl )-7-but-2-ynyl-3-methyl-l-( 4-methyl-quinazo- lin-2-ylmethyl ) -3,7-dihydro-purine-2, 6-dione ( BI1356 ), a novel xanthine-based dipeptidyl peptidase 4 inhibitor, has a su- perior potency and longer duration of action compared with other dipeptidyl peptidase-4 inhibitors [ J ]. J Pharmacol Exp T- her_2008 _325( 1 ) .175-192.
  • 8EMA. Linagliptin [ EB/OL]. [ 2011-09-21 ]. http://www. ema. europa, eu/docs/en _ GB/document _ library/EPAR _-_ Public _ assessment _ report/human/002110/WC500115748. pdf.
  • 9Friedrich C,Port A,Ring A,et al. Effect of multiple oral doses of linagliptin on the steady-state pharmacokinetics of a combi- nation oral contraceptive in healthy female adults:an open-la- bel,two-period, fixed-sequence, multiple-dose study [ J]. Clin Drug Investig,2011,31 (9) :643-653.
  • 10Taskinen MR, Rosenstock J, Tamminen I, et al. Safety and ef- ficacy of linagliptin as add-on therapy to metformin in patients with type 2 diabetes: a randomized, double-blind, placebo-con- trolled study [ J ]. Diabetes Obes Metab ,2011,13 ( 1 ) 65-74.

同被引文献82

  • 1钱荣立.中国糖尿病防治指南[M].北京:北京大学医学出版社,2004:18-11,72.
  • 2Wild S, Roglic G, Green A, et al. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030 [J]. Diabetes Care, 2004,27(10) : 1047-1053.
  • 3Dielemans I, de Jong P T, Stolk R, et al. Primary open-angle glaucoma, intraocular pressure, and diabetes mellitus in the general elderly population. The Rotterdam Study [J]. Ophthalmology, 1996, 103(8) : 1271-1275.
  • 4Mitchell P, Smith W, Chey T, et al. Open-angle glaucoma and diabetes: The Blue Mountains Eye Study [J]. Australia. Ophthalmology, 1997,104(4) :712-718.
  • 5Tan G S, Wong T Y, Fong C W, et al. Singapore Malay Eye Study. Diabetes, metabolic abnormalities, and glaucoma [J]. Arch Ophthalmol, 2009,127(10) : 1354-1361.
  • 6Wu S Y, Leske M C. Associations with intraocular pressure ira the Barbados Eye Study [J]. Arch Ophthalmol, 1997,115(12) : 1572-1576.
  • 7Dielemans I, Vingerling J R, Algra D, et al. Primary openangle glaucoma, intraocular pressure, and systemic blood pressure in the general elderly population [J]. Ophthalmology, 1995,102( 1 ) : 54-60.
  • 8Clark C V, Mapstone R. The prevalence of diabetes mellitus in the family history of patients with primary glaucoma [J]. Doc Ophthalmo], 1986,6 (2) : 161 - 163.
  • 9Mapstone R, Clark C V. Prevalence of diabetes in glaucoma [J]. Br Med J (Clin ResEd), 1985,291(6488):93-95.
  • 10Marcus M W, Mtiskens R P, Ramdas W D, et al. Cholesterol- lowering drugs and incident open-angle glaucoma: a population- based cohort study [J]. PLoS One,2012,7( 1 ):e29724.

引证文献8

二级引证文献30

实用药物与临床
2012年 第8期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部